We're taking a closer look at Alnylam Pharmaceuticals today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -0.1% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
-
Alnylam Pharmaceuticals has moved -9.0% over the last year compared to 16.0% for the S&P 500 -- a difference of -25.0%
-
ALNY has an average analyst rating of buy and is -22.15% away from its mean target price of $247.86 per share
-
Its trailing 12 month earnings per share (EPS) is $-7.88
-
Alnylam Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -24.5 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-2.42 and its forward P/E ratio is -79.7
-
ALNY has a Price to Earnings Growth (PEG) ratio of 0.17, which shows the company is very undervalued compared to its earnings growth estimates.
-
Alnylam Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
Alnylam Pharmaceuticals has on average reported free cash flows of $-405285500.0 over the last four years, during which time they have grown by an an average of -0.0%